These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34433550)

  • 1. Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
    Stoner A; Harris A; Oddone F; Belamkar A; Verticchio Vercellin AC; Shin J; Januleviciene I; Siesky B
    Br J Ophthalmol; 2022 Oct; 106(10):1332-1337. PubMed ID: 34433550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological therapy for glaucoma: a review.
    Hoyng PF; van Beek LM
    Drugs; 2000 Mar; 59(3):411-34. PubMed ID: 10776828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of adverse events in self-reported sulfa-allergic patients using topical carbonic anhydrase inhibitors.
    Guedes GB; Karan A; Mayer HR; Shields MB
    J Ocul Pharmacol Ther; 2013 Jun; 29(5):456-61. PubMed ID: 23445203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
    Lafuma A; Berdeaux G
    Curr Med Res Opin; 2008 May; 24(5):1519-27. PubMed ID: 18413015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical carbonic anhydrase inhibitors: a new perspective in glaucoma therapy.
    Hiett JA; Dockter CA
    Optom Clin; 1992; 2(4):97-112. PubMed ID: 1286242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Trusopt--a new form of drug for treating glaucoma].
    Izdebska J
    Klin Oczna; 1997; 99(3):217-20. PubMed ID: 9456571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of glaucoma: focus on pharmacological therapy.
    Marquis RE; Whitson JT
    Drugs Aging; 2005; 22(1):1-21. PubMed ID: 15663346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical carbonic anhydrase inhibitors: potential adjuvants to glaucoma therapy in the future.
    Scott BT
    Optom Vis Sci; 1994 May; 71(5):332-8. PubMed ID: 8065709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Innovative glaucoma therapy. Glaucoma therapy with topical carbonic anhydrase inhibitors].
    Herkel U; Pfeiffer N
    Ophthalmologe; 2001 Oct; 98(10):929-33. PubMed ID: 11699313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glaucoma: a review of adjunctive therapy and new management strategies.
    Whitson JT
    Expert Opin Pharmacother; 2007 Dec; 8(18):3237-49. PubMed ID: 18035966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclodextrin-based formulation of carbonic anhydrase inhibitors for ocular delivery - A review.
    Jansook P; Hnin HM; Loftsson T; Stefánsson E
    Int J Pharm; 2021 Sep; 606():120955. PubMed ID: 34332063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiglaucoma carbonic anhydrase inhibitors: a patent review.
    Masini E; Carta F; Scozzafava A; Supuran CT
    Expert Opin Ther Pat; 2013; 23(6):705-16. PubMed ID: 23627893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor.
    Pfeiffer N
    Surv Ophthalmol; 1997; 42(2):137-51. PubMed ID: 9381367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical therapies for glaucoma: what family physicians need to know.
    Lewis PR; Phillips TG; Sassani JW
    Am Fam Physician; 1999 Apr; 59(7):1871-9, 1882. PubMed ID: 10208706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects.
    Nesher R; Ticho U
    Isr Med Assoc J; 2003 Apr; 5(4):260-3. PubMed ID: 14509130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population.
    Tzamalis A; Kynigopoulos M; Chalvatzis N; Dimitrakos S; Schlote T
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):41-7. PubMed ID: 23066787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes].
    Viestenz A; Martus P; Schlötzer-Schrehardt U; Langenbucher A; Mardin CY
    Klin Monbl Augenheilkd; 2004 Sep; 221(9):753-6. PubMed ID: 15459842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical carbonic anhydrase inhibitors.
    Talluto DM; Wyse TB; Krupin T
    Curr Opin Ophthalmol; 1997 Apr; 8(2):2-6. PubMed ID: 10168353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
    Balfour JA; Wilde MI
    Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New medical treatments of glaucoma. New strategies?].
    Renard JP; May F; Rigal-Sastourne JC; Maurin JF
    J Fr Ophtalmol; 2001 Dec; 24(10):1095-9. PubMed ID: 11913242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.